Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Responses of state Medicaid programs to buprenorphine diversion: doing more harm than good?

Clark RE, Baxter JD.

JAMA Intern Med. 2013 Sep 23;173(17):1571-2. doi: 10.1001/jamainternmed.2013.9059. Review. No abstract available.

PMID:
23877740
2.

The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence.

Clark RE, Baxter JD, Barton BA, Aweh G, O'Connell E, Fisher WH.

Health Serv Res. 2014 Dec;49(6):1964-79. doi: 10.1111/1475-6773.12201. Epub 2014 Jul 9.

3.

The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine.

Clark RE, Samnaliev M, Baxter JD, Leung GY.

Health Aff (Millwood). 2011 Aug;30(8):1425-33. doi: 10.1377/hlthaff.2010.0532.

4.

Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.

Clark RE, Baxter JD, Aweh G, O'Connell E, Fisher WH, Barton BA.

J Subst Abuse Treat. 2015 Oct;57:75-80. doi: 10.1016/j.jsat.2015.05.001. Epub 2015 May 7.

5.

Financial factors and the implementation of medications for treating opioid use disorders.

Knudsen HK, Roman PM.

J Addict Med. 2012 Dec;6(4):280-6. doi: 10.1097/ADM.0b013e318262a97a.

6.

Opioid use disorder during pregnancy in Tennessee: expediency vs. science.

Martin PR, Finlayson AJ.

Am J Drug Alcohol Abuse. 2015;41(5):367-70. doi: 10.3109/00952990.2015.1047502.

PMID:
26186388
7.

Diversion of methadone and buprenorphine from opioid substitution treatment: patients who regularly sell or share their medication.

Johnson B, Richert T.

J Addict Dis. 2015;34(1):1-17. doi: 10.1080/10550887.2014.975617.

PMID:
25496247
8.

Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.

Curcio F, Franco T, Topa M, Baldassarre C; Gruppo Responsabili UO Sert T.

Eur Rev Med Pharmacol Sci. 2011 Aug;15(8):871-4.

PMID:
21845796
9.

Public policy statement on buprenorphine for opiate dependence and withdrawal.

[No authors listed]

J Addict Dis. 2004;23(4):116-7. No abstract available.

PMID:
15534969
10.

Vermont responds to its opioid crisis.

Simpatico TA.

Prev Med. 2015 Nov;80:10-1. doi: 10.1016/j.ypmed.2015.04.002. Epub 2015 Apr 11.

PMID:
25869219
11.

The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.

Stein BD, Gordon AJ, Sorbero M, Dick AW, Schuster J, Farmer C.

Drug Alcohol Depend. 2012 Jun 1;123(1-3):72-8. doi: 10.1016/j.drugalcdep.2011.10.016. Epub 2011 Nov 16.

PMID:
22093488
12.

Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.

Molfenter T, Sherbeck C, Zehner M, Quanbeck A, McCarty D, Kim JS, Starr S.

Subst Abuse Treat Prev Policy. 2015 Mar 28;10:13. doi: 10.1186/s13011-015-0009-2.

13.

Buprenorphine for opiate addiction: potential economic impact.

Rosenheck R, Kosten T.

Drug Alcohol Depend. 2001 Aug 1;63(3):253-62.

PMID:
11418229
14.

State policy influence on the early diffusion of buprenorphine in community treatment programs.

Ducharme LJ, Abraham AJ.

Subst Abuse Treat Prev Policy. 2008 Jun 20;3:17. doi: 10.1186/1747-597X-3-17.

15.

Management of women treated with buprenorphine during pregnancy.

Alto WA, O'Connor AB.

Am J Obstet Gynecol. 2011 Oct;205(4):302-8. doi: 10.1016/j.ajog.2011.04.001. Epub 2011 Apr 13. Review.

PMID:
21640969
16.

Adherence to Buprenorphine Treatment Guidelines in a Medicaid Program.

Baxter JD, Clark RE, Samnaliev M, Aweh G, O'Connell E.

Subst Abus. 2015;36(2):174-82. doi: 10.1080/08897077.2014.991469.

PMID:
25706332
17.

Factors associated with Medicaid patients' access to buprenorphine treatment.

Baxter JD, Clark RE, Samnaliev M, Leung GY, Hashemi L.

J Subst Abuse Treat. 2011 Jul;41(1):88-96. doi: 10.1016/j.jsat.2011.02.002. Epub 2011 Apr 2.

PMID:
21459544
18.

Integration of buprenorphine for substance-abuse treatment by HIV care providers.

Friedland G, Vlahov D.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S1-2. doi: 10.1097/QAI.0b013e31820bc9ba. No abstract available.

PMID:
21317588
19.

Use and misuse of opioid replacement therapies: a Queensland study.

Smirnov A, Kemp R.

Subst Use Misuse. 2012 Jan;47(1):78-85. doi: 10.3109/10826084.2011.629017.

PMID:
22216993
20.

A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care.

Cheever LW, Kresina TF, Cajina A, Lubran R.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S3-6. doi: 10.1097/QAI.0b013e318209740f.

PMID:
21317591

Supplemental Content

Support Center